Zydus Lifesciences share news, announcements and annual reports
NSE: ZYDUSLIFEBSE: 532321Pharmaceuticals & BiotechnologyMid Cap
Zydus Lifesciences Limited · Formerly Cadila Healthcare · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2000
Last close ₹1,245.50up ₹61.10 (5.16%)BSE ₹1,244.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,184.40.
30 Oct: open ₹1,190.00, high ₹1,248.90, low ₹1,182.00
52-week range of traded prices to 30 Oct 2026
₹835.50Low, 2 Apr 2026₹1,248.90High, 30 Oct 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,24,239 Cr114th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 27.53
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 24.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.58
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.08%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 19.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 36,60,70935.2% delivered
Zydus Lifesciences share news and announcements
1,762 announcements, routine notices left out, newest first. Page 30 of 36.
Jul 2014
31 Jul · Disclosure of Voting Pattern - Clause 35A
9 Jul · Board meeting
To consider amongst other agenda items to approve the unaudited financial results for the quarter ended on June 30, 2014. Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 1992, the Trading Window will remain close from July 21, 2014 to July 31, 2014 for all directors and designated officers of the Company.
Jun 2014
30 Jun · Updates
June 30, 2014 will be the cut-off date for the purpose of offering e-Voting facility to the members in respect of the businesses to be transacted at the Annual General Meeting scheduled to be held on July 30, 2014.2 Jun · Meeting
Register of Members in respect of Equity Shares of the Company shall remain closed from July 21, 2014 to July 30, 2014 (both days inclusive) for the purpose of Annual General Meeting of the Company to be held on July 30, 2014 and payment of dividend for the year ended on March 31, 2014.2 Jun · Dividend
Dividend if declared by the members at the Annual General Meeting to be held on July 30, 2014 will be paid to the members on or after August 4, 2014.
May 2014
16 May · Dividend
Board of Directors of the Company at its meeting held on May 16, 2014 has recommended the payment of dividend of Rs.9/- (180%) on 20,47,48,520 equity shares of Rs.5/- each out of the profits for the year ended on March 31, 2014 for approval by the members at the ensuing Annual General Meeting.
Apr 2014
Feb 2014
Jan 2014
27 Jan · Updates
Company has recently completed portfolio and strategy review of its business and has decided to exit from its business in Japan, which is through 100% subsidiary company.20 Jan · Board meeting
To consider amongst other agenda items to approve the unaudited financial results for the quarter/nine months ended on December 31, 2013. Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI(Prohibition of inisder Trading) Regulations, 1992, the Trading Window will remain close from January 29, 2014 to February 08, 2014 for all Directors and designated officers of the Company.
Dec 2013
Nov 2013
Oct 2013
31 Oct · Results
15 Oct · Board meeting
To consider amongst other agenda items to approve the unaudited financial results for the quarter/ half-year ended on September 30, 2013.
Sep 2013
30 Sep · Disclosure of Voting Pattern - Clause 35A
2 Sep · Meeting
Register of Members in respect of Equity Shares of the Company shall remain closed from September 23, 2013 to September 30, 2013 (both days inclusive) for the purpose of Annual General Meeting of the Company to be held on September 30, 2013.
Aug 2013
22 Aug · Board meeting
To consider amongst other agenda items to consider and approve the audited merged accounts for the financial year ended on March 31, 2013.
Jul 2013
24 Jul · Board meeting
To consider amongst other agenda items to approve the unaudited financial results for the first quarter of the Current financial year ended on June 30, 2013.
Jun 2013
5 Jun · Updates
Zydus Cadila has got approval for India's first new chemical entity (NCE) from the Drug Controller General of India.